2022
DOI: 10.1186/s12913-022-08272-z
|View full text |Cite
|
Sign up to set email alerts
|

Drug repurposing: a systematic review on root causes, barriers and facilitators

Abstract: Background Repurposing is a drug development strategy receiving heightened attention after the Food and Drug Administration granted emergency use authorization of several repurposed drugs to treat Covid-19. There remain knowledge gaps on the root causes, facilitators and barriers for repurposing. Method This systematic review used controlled vocabulary and free text terms to search ABI/Informa, Academic Search Premier, Business Source Complete, Coc… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
46
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 94 publications
(46 citation statements)
references
References 83 publications
0
46
0
Order By: Relevance
“…Eighty percent of repurposed agents are funded through these mechanisms. The disproportionately smaller role played by the biopharmaceutical industry compared to NIH, academics, advocacy, and philanthropic entities in the development of repurposed agents reflects the difficulty ofprotecting intellectual property for generic drugs that comprise the foundation for marketability and return on investment 10,11. Deployment and marketing of a successfully developed repurposed compound requires substantial funding.…”
mentioning
confidence: 99%
“…Eighty percent of repurposed agents are funded through these mechanisms. The disproportionately smaller role played by the biopharmaceutical industry compared to NIH, academics, advocacy, and philanthropic entities in the development of repurposed agents reflects the difficulty ofprotecting intellectual property for generic drugs that comprise the foundation for marketability and return on investment 10,11. Deployment and marketing of a successfully developed repurposed compound requires substantial funding.…”
mentioning
confidence: 99%
“…This report also adds to the broader discussion surrounding the successes and challenges of drug repurposing ( 28 ). Of the hits we identified, colforsin daropate, rhodamine 123, and poziotinib are used for cancer indications and, like the hydrazinophthalazines, have known human targets, implying that selectivity and off-target toxicity are hurdles to be addressed if repurposing for radical cure is to be successful.…”
Section: Discussionmentioning
confidence: 84%
“…Regardless, these results highlight that in vivo P. vivax relapse models should be further developed and validated, as those hits lacking activity in P. cynomolgi might be abandoned for no other reason than the inability to demonstrate in vivo efficacy prior to first-inhuman studies (27). This report also adds to the broader discussion surrounding the successes and challenges of drug repurposing (28). Of the hits we identified, colforsin daropate, rhodamine 123, and poziotinib are used for cancer indications and, like the hydrazinophthalazines, have known human targets, implying that selectivity and off-target toxicity are hurdles to be addressed if repurposing for radical cure is to be successful.…”
Section: Discussionmentioning
confidence: 90%
“…Our work's premise is to utilize a drug's known polypharmacology properties to unlock novel therapeutic opportunities by redesigning its drug delivery system (28). Rosiglitazone is a proven, highly effective drug in treating type Ⅱ diabetes mellitus.…”
Section: Discussionmentioning
confidence: 99%